Journal
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 107, Issue 8, Pages 2148-2153Publisher
ENDOCRINE SOC
DOI: 10.1210/clinem/dgac276
Keywords
obesity; glucagon-like peptide 1; GLP-1 receptor agonists; weight loss
Categories
Ask authors/readers for more resources
Recent clinical trials have shown that GLP-1 receptor agonists are effective and well-tolerated agents for weight loss. Originally developed for glucose control in type 2 diabetes, research over the past 30 years has demonstrated that GLP-1 receptor agonists also reduce food intake by acting in the central nervous system.
Recent evidence from clinical trials supports the efficacy and tolerability of glucagon-like peptide 1 (GLP-1) receptor agonists as useful agents for weight loss. Although originally developed as glucose lowering agents for people with type 2 diabetes, progress in research over the last 3 decades has demonstrated that GLP-1 receptor agonists act in the central nervous system to reduce food intake. This minireview summarizes key aspects of GLP-1 biology and the clinical studies supporting the utility of the GLP-1 receptor signaling system as a therapeutic target for weight loss.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available